Schonfeld Strategic Advisors LLC Macrogenics Inc Transaction History

Schonfeld Strategic Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $406,408 - $2.27 Million	122,782 New	122,782 $521,000
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $341,582 - $770,847	76,246 New	76,246 $733,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $140,868 - $244,296	-46,800 Reduced 42.78%	62,600 $216,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $226,800 - $1.01 Million	100,800 Added 1172.09%	109,400 $323,000
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $176,214 - $306,418	8,600 New	8,600 $231,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.